Bio News

Eli Lilly has signed a drug-development partnership worth up to $3.35 billion with Beijing-based InnoCare in China.
Lilly will pay $100 million upfront and jointly develop compounds against up to five targets.
InnoCare focuses on cancer and autoimmune diseases. The deal is Lilly’s fourth partnership with a Chinese pharmaceutical company since 2025.

Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882